Indication: Urothelial Cancer
A Phase III, Randomized, Open Label, Controlled, Multi-Center, Global Study of First-Line Durvalumab in Combination with Standard of Care Chemotherapy and Durvalumab in Combination with Tremelimumab and Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone in Patients with Unresectable Locally Advanced or Metastatic Urothelial Cancer. (D933SC00001)
Unresectable Locally Advanced or Metastatic
Sub-indication: Unresectable Locally Advanced or Metastatic Urothelial Cancer.
Line of Therapy: 1st Line. (Patients who have received prior definitive chemoradiation, adjuvant or neoadjuvant for locally advanced disease are eligible provided that progression to locally advanced or metastatic disease has occurred >12 months from the last therapy or >12 months from the last surgery.)
Principal Investigator: Arash Rezazadeh, M.D.Norton Cancer Institute
Email for more information: GU-NCIResearch@nortonhealthcare.org